The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

CDC staff received an email this week telling them to avoid using more than a dozen terms or words-- including "health equity ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

The Drone detection market is estimated in terms of market size to be USD 659.4 million in 2024 to USD 2,329.9 million by 2029, at a CAGR of 28.7% according to a new report by MarketsandMarketstm. The ...

A new study released today by B2B order-to-cash software and digital payments market leader Billtrust reveals how Generation Z is fundamentally transforming payment behaviors and expectations. With ...

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...